Strategy Inc. provides a full range of due diligence services for the global medical device industry.

A Strategy Inc. Business Plan clearly articulates a medical technology's opportunity to achieve commercial success through;

• Complete analysis of the market segmentation and competitive positioning
• Development of a viable business model and assumption-driven financial projections
• Identification of realistic capital needs
• Outline of a sustainable growth strategy with well defined milestones

A Strategy Inc. Market Analysis defines a medical technology's potential for commercial success for each of its identified target markets

• Identification of current and emerging treatment modalities and addressable target markets
• Comprehensive evaluation of a range of proven market drivers
• Full assessment of projected barriers to market adoption, target customer profile and market penetration
• In-depth understanding of the pricing and reimbursement landscape

A Strategy Inc. Valuation supports negotiations from a position of strength with a defensible bottom line.

• Can drive refinement of corporate strategy in advance of capital formation and acquisition activities and is:
• Backed by in-depth quantitative financial techniques and market analysis based on current industry trends
• Determined through triangulation of discounted cash flows, industry comparables and valuation by stage
• Supported by a qualitative analysis of the market, current industry trends, and economic conditions

A Strategy Inc. TechSelect analysis determines the commercialization potential of a lifescience technology. TECHSELECT is most often used to compare a number of technologies to determine which has the highest probability to deliver the highest return. The Executive deliverable provides a quantitative comparison of multiple and often very different biomedical technologies applicable for various indications for use through the projection of the following:

• Clinical adoption of a device, pharmaceutical, combination product or biologic
• Commercial interest in the technology at different stages of development
• Competitive advantages of the technologies evaluated
• Drivers and barriers to technology adoption to determine the challenges and their influence
• Projected commercialization risk based on technology evaluation
• Anticipated technology development time to commercialization

A Strategy Inc. Clinical Adoption Projector determines the projected clinical adoption based on global opinion leaders direct input and;

• Assists in forecasting clinical adoption cycles by conducting direct, one-on-one interviews with 15 to 30 carefully selected physicians that each have aligned and significant domain experience
• Delivers a candid opinion from the target market of the medical technology under consideration for development funding
• Addresses the chasm between technology that physicians are "interested in" and technology they would actually purchase
• Includes therapeutic trends and practice patterns, instrumentation features, purchase decisions and cost considerations that influence a technology's selection

A Strategy Inc. Competitive Analysis facilitates the identification and assessment of a potential market "space" and provides;

• Assessment of current, future and emerging direct and indirect competitors
• Comprehensive overview of the competitive market from the financial, technological, sales and marketing and regulatory perspectives

A Strategy Inc. Investor Presentation delivers the core attributes of the technology critical to potential investors to obtain an increased probability of funding with a higher valuation. Emerging entrepreneurs have a vested interest to present their lifescience technology in a financial business format rather than a more familiar scientific layout since funders seek specific information laid out in a brief and focused structure. This is a case where less is definitely more.

• Includes the five critical issues that are key to funders, and they are NOT the management team and revenue projections
• Answers the critical three questions, without which the potential for funding decreases to zero

A Strategy Inc. Risk Analysis outlines the most direct path to successful commercialization while mitigating the known and potential risks of product development

• Understands the specific strengths, weaknesses, opportunities and threats in all developmental aspects
• Encompasses all areas of the medical device development landscape, including technology, clinical, market acceptance, competition, regulatory and financial
• Provides a comprehensive "blue print" to successfully launch an emerging technology in today's medical device market